Mymetics announces publication in npj –Vaccines: “Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
Epalinges, Switzerland, 3 February 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today that results from a study at the Swiss Tropical and Public Health Institute (Swiss TPH) were published on January 31, 2020 in the Nature Partner Journal (npj) Vaccines.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Press Release pdf | Download |